Construction of a risk and prognostic model for migrasome-associated lncRNAs in renal cell carcinoma

Liangwei Zhao1, Fengjiao Geng2, Xiaomin Ji3

  • 1Department of Urology, Huzhou Traditional Chinese Medicine Hospital, Zhejiang Chinese Medical University, Huzhou, 313000, China.

Scientific Reports
|July 23, 2025
PubMed

Insights

Migrasomes and their related long non-coding RNAs (lncRNAs) are crucial for kidney cancer prognosis. A new risk model using these lncRNAs predicts patient outcomes and immune responses in kidney renal clear cell carcinoma.

Area of Science:

  • Cell Biology
  • Oncology
  • Genomics

Background:

  • Migrasomes are novel organelles linked to cell migration.
  • Their role in kidney cancer prognosis is not well understood.
  • Kidney renal clear cell carcinoma (KIRC) is a significant health concern.

Purpose of the Study:

  • To investigate the prognostic significance of migrasome-related long non-coding RNAs (lncRNAs) in KIRC.
  • To develop and validate a prognostic risk model for KIRC patients.
  • To explore the relationship between migrasome-related lncRNAs, prognosis, and tumor immunity.

Main Methods:

  • Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression analysis on TCGA-KIRC data.
  • Identification of prognostic migrasome-related lncRNAs.
  • Development and validation of a prognostic risk model.
  • Analysis of tumor immune dysfunction and exclusion scores.
  • Immune cell infiltration profiling.

Main Results:

  • Twelve migrasome-related lncRNAs were identified as significantly associated with KIRC prognosis.
  • The developed prognostic model effectively stratified patients into high- and low-risk groups.
  • Higher risk scores correlated with significantly worse prognosis and increased immune cell infiltration.

Conclusions:

  • Migrasome-related lncRNAs are important prognostic indicators in KIRC.
  • The developed risk model offers a novel tool for predicting KIRC patient prognosis.
  • This model may also aid in predicting patient immune response, potentially guiding immunotherapy strategies.